117 related articles for article (PubMed ID: 9111582)
1. Effects of colony-stimulating factors on cellular cytotoxicity.
Durek C; Schäfer I; Braasch H; Ulmer AJ; Ernst M; Flad HD; Jocham D; Böhle A
Cancer Immunol Immunother; 1997 Mar; 44(1):35-40. PubMed ID: 9111582
[TBL] [Abstract][Full Text] [Related]
2. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of monocytes to lymphokine-activated killer cell lysis: effect of granulocyte-macrophage colony-stimulating factor and interleukin-3.
Djeu JY; Widen R; Blanchard DK
Blood; 1989 Apr; 73(5):1264-71. PubMed ID: 2649172
[TBL] [Abstract][Full Text] [Related]
4. Induction of human monocyte susceptibility to lymphokine-activated killer cell lysis by granulocyte-macrophage colony-stimulating factor.
Blanchard DK; Serbousek D; Djeu JY
Cancer Res; 1989 Sep; 49(18):5037-43. PubMed ID: 2670200
[TBL] [Abstract][Full Text] [Related]
5. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
Singh SM; Sone S; Inamura N; Ogura T
Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
8. Killing of alveolar macrophages and of monocytes that have responded to granulocyte-macrophage colony-stimulating factor by human lymphokine-activated killer cells.
Sone S; Inamura N; Singh SM; Okubo A; Yanagawa H; Nakanishi M; Ogura T
Jpn J Cancer Res; 1989 Jul; 80(7):662-9. PubMed ID: 2507489
[TBL] [Abstract][Full Text] [Related]
9. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.
Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ
Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241
[TBL] [Abstract][Full Text] [Related]
10. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
11. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
[TBL] [Abstract][Full Text] [Related]
12. The effects of recombinant human granulocyte-macrophage colony-stimulating factor on the induction of lymphokine-activated killer cells in vitro.
Okamura S; Tanaka T; Yamaga S; Omori F; Niho Y
Int J Immunopharmacol; 1991; 13(5):587-93. PubMed ID: 1783473
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients.
Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
Cancer Immunol Immunother; 2000 Dec; 49(10):537-43. PubMed ID: 11129324
[TBL] [Abstract][Full Text] [Related]
14. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
15. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
[TBL] [Abstract][Full Text] [Related]
17. Differential augmentation of in vivo natural killer cytotoxicity in normal primates with recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor.
Davis TA; Monroy RL; Skelly RR; Donahue RE; MacVittie TJ
Clin Exp Immunol; 1990 Mar; 79(3):436-42. PubMed ID: 2180599
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.
Ragnhammar P; Frödin JE; Trotta PP; Mellstedt H
Cancer Immunol Immunother; 1994 Oct; 39(4):254-62. PubMed ID: 7525059
[TBL] [Abstract][Full Text] [Related]
20. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients.
Joshi SS; Miller K; Jackson JD; Warkentin P; Kessinger A
Cytotherapy; 2000; 2(1):15-24. PubMed ID: 12042051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
